Investigating the effect of ciliary body photodynamic therapy in a glaucoma mouse model

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 6, 2006, Pages 2498-2507

  Matsubara, Akihisa ^a   Nakazawa, Toru ^a   Husain, Deeba ^b   Iliaki, Eirini ^a   Connolly, Edward ^a   Michaud, Norman A ^a   Gragoudas, Evangelos S ^a   Miller, Joan W ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYE; GLASS FIBER; VERTEPORFIN; BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; PORPHYRIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL COUNT; CELL LOSS; CELL SURVIVAL; CILIARY BODY; CILIARY BODY EPITHELIUM; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA LIMBUS; DBA 2 MOUSE; DRUG EFFECT; ELECTRON MICROSCOPY; EYE; EYE INJURY; FEMALE; FIBER OPTIC BIOSENSOR; GLAUCOMA; INTRAOCULAR PRESSURE; LASER; LIGHT; LIGHT IRRADIANCE; MORPHOLOGY; MOUSE; NONHUMAN; OCULAR BLOOD VESSEL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA GANGLION CELL; RETREATMENT; STATISTICAL SIGNIFICANCE; STROMA; THERAPY EFFECT; THROMBOSIS; TONOMETER; ANIMAL; C57BL MOUSE; DBA MOUSE; DISEASE MODEL; DOSE RESPONSE; METABOLISM; NICK END LABELING; OCULOPLETHYSMOGRAPHY; PATHOLOGY; PHOTOCHEMOTHERAPY; ULTRASTRUCTURE; VASCULARIZATION;

ANIMALS; CELL COUNT; CILIARY BODY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLAUCOMA; IN SITU NICK-END LABELING; INTRAOCULAR PRESSURE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETINAL GANGLION CELLS; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745653708     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0959     Document Type: Article

References (38)

1. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
2. Rodriguez J, Sanchez R, Munoz B, et al. Causes of blindness and visual impairment in a population-based sample of U.S. Hispanics Ophthalmol. 2002;109:737-743.
3. Bietti G. Surgical intervention on the ciliary body: New trends for the relief of glaucoma. JAMA. 1950;142:889-897.
4. Weekers R, Lavergne G, Watillon M, Gilson M, Legros AM. Effects of photocoagulation of ciliary body upon ocular tension. Am J Ophthalmol. 1961;52:156-163.
5. Smith RS, Stein MN. Ocular hazards of transscleral laser radiation. II. Intraocular injury produced by ruby and neodymium lasers. Am J Ophthalmol. 1969;67:100-110.
6. Beckman H, Waeltermann J. Transscleral ruby laser cyclocoagulation. Am J Ophthalmol. 1984;98:788-795.
7. Haddad R. Cyclocryotherapy: experimental studies of the breakdown of the blood-aqueous barrier and analysis of a long-term follow-up study [in German]. Wien Klin Wochenschr Suppl. 1981;126:1-18.
8. Kaiden JS, Serniuk RA, Bader BF. Choroidal detachment with flat anterior chamber after cyclocryotherapy. Ann Ophthalmol. 1979;11:1111-1113.
9. Hill RA, Esterowitz T, Ryan J, et al. Photodynamic laser cyclodestruction with chloroaluminum sulfonated phthalocyanine (CASPc) or Photofrin (PII) vs. Nd:YAG laser cyclodestruction in a pigmented rabbit model. Lasers Surg Med. 1995;17:166-171.
10. Hill RA, Garrett J, Reddi S, et al. Photodynamic therapy (PDT) of the ciliary body with silicon naphthalocyanine (SINc) in rabbits. Lasers Surg Med. 1996;18:86-91.
11. Hill RA, Crean DH, Doiron DR, et al. Photodynamic therapy of the ciliary body with tin ethyl etiopurpurin and tin octaethyl benzochlorin in pigmented rabbits. Ophthalmic Surg Lasers. 1997;28:948-953.
12. Tsilimbaris MK, Naoumidi II, Naoumidis LP, Papageorgiou E, Pallikaris IG. Transscleral ciliary body photodynamic therapy using phthalocyanine and a diode laser: functional and morphologic implications in albino rabbits. Ophthalmic Surg Lasers. 1997;28:483-494.
13. Tsilimbaris MK, Naoumidi II, Kozombolis VP, Naoumidi TL, Daskalakis M, Pallikaris IG. Ciliary body PDT in pigmented rabbit eyes: effect of single and repeated treatment. Curr Eye Res. 2000;20:469-479.
14. Verteporfin Roundtable 2000 and 2001 Participants. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002;22:6-18.
15. Richter AM, Waterfield E, Jain AK, Sternberg ED, Dolphin D, Levy JG. In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives. Photochem Photobiol. 1990;52:495-500.
16. Richter AM, Waterfield E, Jain AK, et al. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. Br J Cancer. 1991;63:87-93.
17. Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer. 1994;69:833-839.
18. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995;113:810-818.
19. Scott LJ, Goa KL. Verteporfin. Drugs Aging. 2000;16:139-146; discussion 147-138.
20. Zheng G, Bachinsky DR, Stamenkovic I, et al. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpa 2MR, and the receptor-associated protein (RAP). J Histochem Cytochem. 1994;42:531-542.
21. Festing MFW. Inbred Strains in Biomedical Research. New York: Oxford University Press; 1979:190-193.
22. Epstein RJ, Halkias A, Stulting DR, Rodrigues MM. Corneal opacities and anterior segment anomalies in DBA/2 Mice. Cornea. 1986;55:169-184.
23. Sheldon WG, Warbritton AR, Bucci TJ, Turturro A. Glaucoma in food-restricted and ad libitum-fed DBA/2NNia mice. Lab Anim Sci. 1995;45:508-518.
24. John SW, Smith RS, Savinova OV, et al. Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci. 1998;39:951-962.
25. Filippopoulos T, Matsubara A, Danias J, et al. Predictability and limitations of non-invasive murine tonometry: comparison of two devices. Exp Eye Res. In press.
26. John SW, Hagaman JR, MacTaggart TE, Peng L, Smithes O. Intraocular pressure in inbred mouse strains. Invest Ophthalmol Vis Sci. 1997;38:249-253.
27. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci. 2000;41:4169-4174.
28. Danias J, Lee KC, Zamora MF, et al. Quantitative analysis of retinal ganglion cell (RGC) loss in aging DBA/2NNia glaucomatous mice: comparison with RGC loss in aging C57BL/6 mice. Invest Ophthalmol Vis Sci. 2003;44:5151-5162.
29. Nakazawa T, Tamai M, Mori N. Brain-derived neurotrophic factor prevents axotomized retinal ganglion cell death through MAPK and PI3K signaling pathways. Invest Ophthalmol Vis Sci. 2002;43:3319-3326.
30. Foster TH, Primavera MC, Marder VJ, Hilf R, Sporn LA. Photosensitized release of von Willebrand factor from cultured human endothelial cells. Cancer Res. 1991;51:3261-3266.
31. van den Bergh H, Ballini JP. Principles of photodynamic therapy. In: Gragoudas ES, Miller JW, Zografos L, eds. Photodynamic Therapy of Ocular Diseases. Philadelphia: Lippincott Williams & Wilkins; 2004:11-42.
32. Sporn LA, Foster TH. Photofrin and light induces microtubule depolymerization in cultured human endothelial cells. Cancer Res. 1992;52:3443-3448.
33. Cantor LB, Nichols DA, Katz LJ, et al. Neodymium-YAG transscleral cyclophotocoagulation: the role of pigmentation. Invest Ophthalmol Vis Sci. 1989;30:1834-1837.
34. Wilensky JT, Welch D, Mirolovich M. Transscleral cyclocoagulation using a neodymium:YAG laser. Ophthalmic Surg. 1985;16:95-98.
35. van der Zypen E, England C, Fankhauser F, Kwasniewska S. The effect of transscleral laser cyclophotocoagulation on rabbit ciliary body vascularization. Graefes Arch Clin Exp Ophthalmol. 1989;227:172-179.
36. Latina MA, Patel S, de Kater AW, Goode S, Nishioka NS, Puliafito CA. Transscleral cyclophotocoagulation using a contact laser probe: a histologic and clinical study in rabbits. Lasers Surg Med. 1989;9:465-470.
37. Mo JS, Anderson MG, Gregory M, et al. By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma. J Exp Med. 2003;197:1335-1344.
38. Schuettauf F, Quinto K, Naskar R, Zurakowski D. Effects of antiglaucoma medications on ganglion cell survival: the DBA/2J mouse model. Vision Res. 2002;42:2333-2337.